Cargando…
Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial
BACKGROUND: Acute respiratory distress syndrome (ARDS) results in significant hypoxia, and ARDS is the central pathology of COVID-19. Inhaled prostacyclin has been proposed as a therapy for ARDS, but data regarding its role in this syndrome are unavailable. Therefore, we investigated whether inhaled...
Autores principales: | Haeberle, Helene A., Calov, Stefanie, Martus, Peter, Serna-Higuita, Lina Maria, Koeppen, Michael, Goll, Almuth, Bernard, Alice, Zarbock, Alexander, Meersch, Melanie, Weiss, Raphael, Mehrländer, Martin, Marx, Gernot, Putensen, Christian, Bakchoul, Tamam, Magunia, Harry, Nieswandt, Bernhard, Mirakaj, Valbona, Rosenberger, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938510/ https://www.ncbi.nlm.nih.gov/pubmed/36805707 http://dx.doi.org/10.1186/s12931-023-02346-0 |
Ejemplares similares
-
COVID-19 does not influence functional status after ARDS therapy
por: Bernard, Alice, et al.
Publicado: (2023) -
Early Driving Pressure Changes Predict Outcomes during Venovenous Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome
por: Magunia, Harry, et al.
Publicado: (2020) -
Early vvECMO implantation may be associated with lower mortality in ARDS
por: Rosenberger, Peter, et al.
Publicado: (2023) -
Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS
por: Häberle, Helene, et al.
Publicado: (2021) -
Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study
por: Haeberle, Helene, et al.
Publicado: (2020)